- Home
- CPS vs ZNTL Comparison
CPS vs ZNTL Comparison
Compare CPS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- ZNTL
- Stock Information
- Founded
- CPS 1960
- ZNTL 2014
- Country
- CPS United States
- ZNTL United States
- Employees
- CPS N/A
- ZNTL N/A
- Industry
- CPS Auto Parts:O.E.M.
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- ZNTL Health Care
- Exchange
- CPS Nasdaq
- ZNTL Nasdaq
- Market Cap
- CPS 368.7M
- ZNTL 105.8M
- IPO Year
- CPS N/A
- ZNTL 2020
- Fundamental
- Price
- CPS $21.78
- ZNTL $1.20
- Analyst Decision
- CPS Hold
- ZNTL Buy
- Analyst Count
- CPS 1
- ZNTL 7
- Target Price
- CPS $12.00
- ZNTL $8.60
- AVG Volume (30 Days)
- CPS 209.8K
- ZNTL 1.4M
- Earning Date
- CPS 07-31-2025
- ZNTL 08-08-2025
- Dividend Yield
- CPS N/A
- ZNTL N/A
- EPS Growth
- CPS N/A
- ZNTL N/A
- EPS
- CPS N/A
- ZNTL N/A
- Revenue
- CPS $2,721,537,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- CPS N/A
- ZNTL N/A
- Revenue Next Year
- CPS $5.00
- ZNTL N/A
- P/E Ratio
- CPS N/A
- ZNTL N/A
- Revenue Growth
- CPS N/A
- ZNTL N/A
- 52 Week Low
- CPS $10.38
- ZNTL $1.01
- 52 Week High
- CPS $26.73
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- CPS 49.74
- ZNTL 43.44
- Support Level
- CPS $19.32
- ZNTL $1.31
- Resistance Level
- CPS $20.67
- ZNTL $1.39
- Average True Range (ATR)
- CPS 0.89
- ZNTL 0.13
- MACD
- CPS -0.23
- ZNTL -0.02
- Stochastic Oscillator
- CPS 39.58
- ZNTL 6.83
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.